Search

Madrigal Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

512.28 -0.83

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

513

Maximum

519.94

Fő mutatók

By Trading Economics

Bevétel

36M

-58M

Értékesítés

53M

364M

Egy részvényre jutó nyereség

-1.99

Profit margin

-15.906

Munkavállalók

915

EBITDA

30M

-56M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+33.35% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-583M

12B

Előző nyitás

513.11

Előző zárás

512.28

Hangulat hírek alapján

By Acuity

48%

52%

141 / 340 Rangsor szerint Healthcare

Madrigal Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 21. 19:46 UTC

Madrigal Pharmaceuticals is lower in Friday's session, retracing from an earlier peak amid broader market pressures from rising Treasury yields and inflation concerns.

2026. aug. 20. 23:46 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading. Broader market declines are attributed to rising crude oil prices and geopolitical tensions.

2026. aug. 18. 19:56 UTC

Madrigal Pharmaceuticals shares are lower today amid rising Treasury yields, which may be influencing investor sentiment. Earlier, the stock pulled back from a session high.

2026. aug. 17. 19:35 UTC

Madrigal Pharmaceuticals is trading higher today, continuing gains since Friday's close, despite no specific company news driving the upward movement.

2026. aug. 14. 19:26 UTC

Social Media

Madrigal Pharmaceuticals launches a Phase 2a study for resmetirom. Shares are lower today, pulled back from earlier gains amid broader market concerns over retail sales.

2026. aug. 13. 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, showing notable movement since Thursday's close, though no specific news explains the price action.

2026. aug. 12. 21:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading. Positive market sentiment follows comments on CPI reports that may impact Federal Reserve interest rate decisions.

2026. aug. 10. 19:16 UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

2026. aug. 7. 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

2026. aug. 6. 21:01 UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

2026. aug. 4. 20:04 UTC

Social Media
News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

2026. aug. 3. 19:31 UTC

News
Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

2026. júl. 31. 23:06 UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

2026. júl. 30. 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

2026. júl. 29. 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

2026. júl. 28. 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

2026. júl. 27. 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

2026. júl. 20. 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Társak összehasonlítása

Árváltozás

Madrigal Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

33.35% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 689.08 USD  33.35%

Magas 962 USD

Alacsony 543 USD

13 Wall Street elemző 12 hónapos célárain alapulva a(z)Madrigal Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

13 ratings

12

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

141 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat